PURPOSE: Because inherited BRCA1 or BRCA2 mutations strikingly increase ovarian cancer risk, polymorphisms in these genes could represent low penetrance susceptibility alleles. Previous studies of the BRCA2 N372H polymorphism suggested that HH homozygotes have a modestly increased risk of both breast and ovarian cancer. We have examined whether BRCA2 N372H or common amino acid-changing polymorphisms in BRCA1 predispose to ovarian cancer. EXPERIMENTAL DESIGN: A population-based, case control study of ovarian cancer was performed in North Carolina. Cases included 312 women with ovarian cancer (76% invasive and 24% borderline) and 401 age- and race-matched controls. Blood DNA from subjects was genotyped for BRCA2 N372H and BRCA1 Q356R and P871L. RESULTS: There was no association between BRCA2 N372H and risk of borderline or invasive epithelial ovarian cancer. The overall odds ratio (OR) for HH homozygotes was 0.8 [95% confidence interval (CI) = 0.4-1.5] and was similar in all subsets, including invasive serous cases. In addition, neither the BRCA1 Q356R (OR = 0.9, 95% CI 0.5-1.4) nor P871L (OR = 0.9, 95% CI 0.6-1.9) polymorphisms were associated with ovarian cancer risk. There was a significant racial difference in allele frequencies of the P871L polymorphism (P = 0.64 in Caucasians, L = 0.76 in African-Americans, P < 0.0001). CONCLUSIONS: In this population-based, case control study, common amino acid changing BRCA1 and 2 polymorphisms were not found to affect the risk of developing ovarian cancer.
PURPOSE: Because inherited BRCA1 or BRCA2 mutations strikingly increase ovarian cancer risk, polymorphisms in these genes could represent low penetrance susceptibility alleles. Previous studies of the BRCA2N372H polymorphism suggested that HH homozygotes have a modestly increased risk of both breast and ovarian cancer. We have examined whether BRCA2N372H or common amino acid-changing polymorphisms in BRCA1 predispose to ovarian cancer. EXPERIMENTAL DESIGN: A population-based, case control study of ovarian cancer was performed in North Carolina. Cases included 312 women with ovarian cancer (76% invasive and 24% borderline) and 401 age- and race-matched controls. Blood DNA from subjects was genotyped for BRCA2N372H and BRCA1Q356R and P871L. RESULTS: There was no association between BRCA2N372H and risk of borderline or invasive epithelial ovarian cancer. The overall odds ratio (OR) for HH homozygotes was 0.8 [95% confidence interval (CI) = 0.4-1.5] and was similar in all subsets, including invasive serous cases. In addition, neither the BRCA1Q356R (OR = 0.9, 95% CI 0.5-1.4) nor P871L (OR = 0.9, 95% CI 0.6-1.9) polymorphisms were associated with ovarian cancer risk. There was a significant racial difference in allele frequencies of the P871L polymorphism (P = 0.64 in Caucasians, L = 0.76 in African-Americans, P < 0.0001). CONCLUSIONS: In this population-based, case control study, common amino acid changing BRCA1 and 2 polymorphisms were not found to affect the risk of developing ovarian cancer.
Authors: Yakir Segev; Tuya Pal; Barry Rosen; John R McLaughlin; Thomas A Sellers; Harvey A Risch; Shiyu Zhang; Sun Ping; Steven A Narod; Joellen Schildkraut Journal: Int J Gynecol Cancer Date: 2013-07 Impact factor: 3.437
Authors: Deirdre A Hill; Sophia S Wang; James R Cerhan; Scott Davis; Wendy Cozen; Richard K Severson; Patricia Hartge; Sholom Wacholder; Meredith Yeager; Stephen J Chanock; Nathaniel Rothman Journal: Blood Date: 2006-07-20 Impact factor: 22.113
Authors: Mohammad R Akbari; Shiyu Zhang; Deborah Cragun; Ji-Hyun Lee; Domenico Coppola; John McLaughlin; Harvey A Risch; Barry Rosen; Patricia Shaw; Thomas A Sellers; Joellen Schildkraut; Steven A Narod; Tuya Pal Journal: Fam Cancer Date: 2017-07 Impact factor: 2.375
Authors: Domenico Coppola; Santo V Nicosia; Andrea Doty; Thomas A Sellers; Ji-Hyun Lee; Jimmy Fulp; Zachary Thompson; Sanja Galeb; John McLaughlin; Steven A Narod; Joellen Schildkraut; Tuya Pal Journal: Anticancer Res Date: 2012-11 Impact factor: 2.480
Authors: Ji-Hyun Lee; Deborah Cragun; Zachary Thompson; Domenico Coppola; Santo V Nicosia; Mohammad Akbari; Shiyu Zhang; John McLaughlin; Steven Narod; Joellen Schildkraut; Thomas A Sellers; Tuya Pal Journal: Genet Test Mol Biomarkers Date: 2014-03-04
Authors: Julie A Douglas; Albert M Levin; Kimberly A Zuhlke; Anna M Ray; Gregory R Johnson; Ethan M Lange; David P Wood; Kathleen A Cooney Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-06-21 Impact factor: 4.254